Literature DB >> 33429022

Role of necroptosis in chronic hepatic inflammation and fibrosis in a mouse model of increased oxidative stress.

Sabira Mohammed1, Evan H Nicklas2, Nidheesh Thadathil2, Ramasamy Selvarani2, Gordon H Royce2, Michael Kinter3, Arlan Richardson4, Sathyaseelan S Deepa5.   

Abstract

Mice deficient in the antioxidant enzyme Cu/Zn-superoxide dismutase (Sod1-/- or Sod1KO mice) have increased oxidative stress, show accelerated aging and develop spontaneous hepatocellular carcinoma (HCC) with age. Similar to humans, HCC development in Sod1KO mice progresses from non-alcoholic fatty liver disease (NAFLD) to non-alcoholic steatohepatitis (NASH) with fibrosis, which eventually progresses to HCC. Oxidative stress plays a role in NAFLD to NASH progression, and liver inflammation is the main mechanism that drives the disease progression from NASH to fibrosis. Because necroptosis is a major source of inflammation, we tested the hypothesis that increased necroptosis in the liver plays a role in increased inflammation and fibrosis in Sod1KO mice. Phosphorylation of MLKL (P-MLKL), a well-accepted marker of necroptosis, and expression of MLKL protein were significantly increased in the livers of Sod1KO mice compared to wild type (WT) mice indicating increased necroptosis. Similarly, phosphorylation of RIPK3 and RIPK3 protein levels were also significantly increased. Markers of pro-inflammatory M1 macrophages, NLRP3 inflammasome, and transcript levels of pro-inflammatory cytokines and chemokines, e.g., TNFα, IL-6, IL-1β, and Ccl2 that are associated with human NASH, were significantly increased. Expression of antioxidant enzymes and heat shock proteins, and markers of fibrosis and oncogenic transcription factor STAT3 were also upregulated and autophagy was downregulated in the livers of Sod1KO mice. Short term treatment of Sod1KO mice with necrostatin-1s (Nec-1s), a necroptosis inhibitor, reversed these conditions. Our data show for the first time that necroptosis-mediated inflammation contributes to fibrosis in a mouse model of increased oxidative stress and accelerated aging, that also exhibits progressive HCC development.
Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Autophagy; Cu/Zn superoxide dismutase; Fibrosis; Hepatocellular carcinoma; Inflammation; Necroptosis; Necrostatin-1s; Non-alcoholic fatty liver disease; Non-alcoholic hepatosteatosis; Oxidative stress

Mesh:

Year:  2021        PMID: 33429022      PMCID: PMC8845573          DOI: 10.1016/j.freeradbiomed.2020.12.449

Source DB:  PubMed          Journal:  Free Radic Biol Med        ISSN: 0891-5849            Impact factor:   7.376


  77 in total

1.  Loss of hepatic NF-kappa B activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation.

Authors:  Toshiharu Sakurai; Shin Maeda; Lufen Chang; Michael Karin
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-28       Impact factor: 11.205

Review 2.  Liver Cancer: Connections with Obesity, Fatty Liver, and Cirrhosis.

Authors:  Andrea Marengo; Chiara Rosso; Elisabetta Bugianesi
Journal:  Annu Rev Med       Date:  2015-10-14       Impact factor: 13.739

Review 3.  The potential role of necroptosis in inflammaging and aging.

Authors:  Gordon H Royce; Holly M Brown-Borg; Sathyaseelan S Deepa
Journal:  Geroscience       Date:  2019-11-13       Impact factor: 7.713

Review 4.  Necroptosis and its role in inflammation.

Authors:  Manolis Pasparakis; Peter Vandenabeele
Journal:  Nature       Date:  2015-01-15       Impact factor: 49.962

5.  Discovery of a Highly Potent, Selective, and Metabolically Stable Inhibitor of Receptor-Interacting Protein 1 (RIP1) for the Treatment of Systemic Inflammatory Response Syndrome.

Authors:  Yan Ren; Yaning Su; Liming Sun; Sudan He; Lingjun Meng; Daohong Liao; Xiao Liu; Yongfen Ma; Chunyan Liu; Sisi Li; Hanying Ruan; Xiaoguang Lei; Xiaodong Wang; Zhiyuan Zhang
Journal:  J Med Chem       Date:  2017-01-05       Impact factor: 7.446

Review 6.  Necroptosis in development, inflammation and disease.

Authors:  Ricardo Weinlich; Andrew Oberst; Helen M Beere; Douglas R Green
Journal:  Nat Rev Mol Cell Biol       Date:  2016-12-21       Impact factor: 94.444

7.  Phosphorylation-activity relationships of AMPK and acetyl-CoA carboxylase in muscle.

Authors:  S H Park; S R Gammon; J D Knippers; S R Paulsen; D S Rubink; W W Winder
Journal:  J Appl Physiol (1985)       Date:  2002-06

Review 8.  Inflammasomes in Liver Fibrosis.

Authors:  Fernando Alegre; Pablo Pelegrin; Ariel E Feldstein
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

9.  Necrostatin-1 analogues: critical issues on the specificity, activity and in vivo use in experimental disease models.

Authors:  N Takahashi; L Duprez; S Grootjans; A Cauwels; W Nerinckx; J B DuHadaway; V Goossens; R Roelandt; F Van Hauwermeiren; C Libert; W Declercq; N Callewaert; G C Prendergast; A Degterev; J Yuan; P Vandenabeele
Journal:  Cell Death Dis       Date:  2012-11-29       Impact factor: 8.469

Review 10.  Update in global trends and aetiology of hepatocellular carcinoma.

Authors:  Prashanth Rawla; Tagore Sunkara; Pradhyumna Muralidharan; Jeffrey Pradeep Raj
Journal:  Contemp Oncol (Pozn)       Date:  2018-09-30
View more
  12 in total

1.  Hydrogen Sulfide Suppresses Skin Fibroblast Proliferation via Oxidative Stress Alleviation and Necroptosis Inhibition.

Authors:  Ling Li; Ziying He; Yue Zhu; Qiyan Shen; Shengju Yang; Shuanglin Cao
Journal:  Oxid Med Cell Longev       Date:  2022-06-21       Impact factor: 7.310

Review 2.  The Role of H2S Regulating NLRP3 Inflammasome in Diabetes.

Authors:  Huijie Zhao; Huiyang Liu; Yihan Yang; Honggang Wang
Journal:  Int J Mol Sci       Date:  2022-04-27       Impact factor: 6.208

Review 3.  Inflammasomes and Pyroptosis of Liver Cells in Liver Fibrosis.

Authors:  Can Gan; Qiuyu Cai; Chengwei Tang; Jinhang Gao
Journal:  Front Immunol       Date:  2022-05-30       Impact factor: 8.786

4.  Selenotranscriptome Network in Non-alcoholic Fatty Liver Disease.

Authors:  Kaitlin Day; Lucia A Seale; Ross M Graham; Barbara R Cardoso
Journal:  Front Nutr       Date:  2021-11-17

5.  Necroptosis increases with age in the brain and contributes to age-related neuroinflammation.

Authors:  Nidheesh Thadathil; Evan H Nicklas; Sabira Mohammed; Tommy L Lewis; Arlan Richardson; Sathyaseelan S Deepa
Journal:  Geroscience       Date:  2021-09-13       Impact factor: 7.713

6.  Necroptosis contributes to chronic inflammation and fibrosis in aging liver.

Authors:  Sabira Mohammed; Nidheesh Thadathil; Ramasamy Selvarani; Evan H Nicklas; Dawei Wang; Benjamin F Miller; Arlan Richardson; Sathyaseelan S Deepa
Journal:  Aging Cell       Date:  2021-11-11       Impact factor: 9.304

Review 7.  Roles of necroptosis in alcoholic liver disease and hepatic pathogenesis.

Authors:  Ying Zhou; Ruoman Wu; Xinqi Wang; Xiaofeng Bao; Chunfeng Lu
Journal:  Cell Prolif       Date:  2022-01-26       Impact factor: 6.831

8.  Glycyrrhetinic acid regulates impaired macrophage autophagic flux in the treatment of non-alcoholic fatty liver disease.

Authors:  Yadong Fan; Wenjin Dong; Ying Wang; Shan Zhu; Rundong Chai; Zhe Xu; Xiaoyu Zhang; Yiqi Yan; Long Yang; Yuhong Bian
Journal:  Front Immunol       Date:  2022-07-28       Impact factor: 8.786

9.  Senolytic treatment reduces cell senescence and necroptosis in Sod1 knockout mice that is associated with reduced inflammation and hepatocellular carcinoma.

Authors:  Nidheesh Thadathil; Ramasamy Selvarani; Sabira Mohammed; Evan H Nicklas; Albert L Tran; Maria Kamal; Wenyi Luo; Jacob L Brown; Marcus M Lawrence; Agnieszka K Borowik; Benjamin F Miller; Holly Van Remmen; Arlan Richardson; Sathyaseelan S Deepa
Journal:  Aging Cell       Date:  2022-07-23       Impact factor: 11.005

Review 10.  Examination of the role of necroptotic damage-associated molecular patterns in tissue fibrosis.

Authors:  Xu Liu; Feng Lu; Xihang Chen
Journal:  Front Immunol       Date:  2022-08-30       Impact factor: 8.786

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.